Navigation Links
Once-Promising Heart Failure Drug Fails in Trial
Date:10/7/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Oct. 6 (HealthDay News) -- A new experimental drug for treating patients who have acute heart failure plus kidney failure did not show any overall benefit, indicating that the future of this particular drug, called rolofylline, is over.

"I think this is the end of the story for this drug," said Dr. Barry Massie, lead author of a study appearing in the Oct. 7 issue of the New England Journal of Medicine. "There was a very promising pilot trial but these results . . . were neutral. I am disappointed," he said.

The results were presented last year at the European Society of Cardiology meeting. Shortly before that, drug company Merck, which has been developing the medicine and which funded this study, announced that it would not be filing for U.S. Food and Drug Administration approval for rolofylline.

Rolofylline is known as an A1-receptor antagonist and is intended to make diuretics work more effectively.

Other drugs in the same class of medications that were developed by other companies have met with similarly disappointing results after promising early results, said Massie, who is chief of the cardiology division at the San Francisco VA Medical Center and professor of medicine at the University of California, San Francisco.

He explained that kidney problems are a major complication of heart failure and "those patients who develop renal [kidney] failure in the course of treatment have a much higher hospital admission and death rate."

This may be at least partly because patients are taken off of certain cardiac medications in order to improve kidney function.

"This is sort of a perfect storm," Massie said.

For this study, just over 2,000 patients who had been hospitalized for acute heart failure and kidney problems were randomly assigned to receive a placebo or 30 milligrams of rolofylline daily intravenously. Treatment las
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Workplace Noise Tied to Heart Disease Risk
2. Testosterone Could Boost Health of Heart Failure Patients
3. Dental Care Linked to Heart Health in Older Women
4. Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment
5. Women who get dental care have lower risk of heart disease, says study
6. WUSTL awarded $18 million to treat heart, lungs with nanotechnology
7. Researchers use CT to predict heart disease
8. ESC announces new initiatives for workplace heart health programs
9. Disparities in heart attack treatment may begin in the emergency room
10. Molecular playbook for halting heart failure risk factor uncovered
11. Surgery May Be Best for Irregular Heartbeat in Young
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Once-Promising Heart Failure Drug Fails in Trial
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... 18 years of research and experience with patients from ... Jon Petrick is excited to be launching his breakthrough ... immediate benefits of this radical new system are increased ... of the immune system, faster healing of injuries, rapid ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... 27, 2015 Florida Hospital is excited to ... team’s exclusive health care provider for the 2015 and 2016 ... provides medical care and an athletic trainer for the team ... off its season against the Cleveland Gladiators at Amalie Arena; ... is extremely important to us as it gives us the ...
(Date:3/27/2015)... March 27, 2015 Bleeding is ... undergoing percutaneous coronary intervention (PCI), resulting in increased ... a “risk-treatment paradox,” in which the highest-risk PCI ... are treated less often with bleeding avoidance strategies ... Luke’s Mid America Heart Institute asked the question ...
Breaking Medicine News(10 mins):Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... of percutaneous coronary intervention (PCI) is now the recommended ... European guidelines issued in November 2008 emphasised speed of ... blood flow to the heart and improve survival rates. ... with stable coronary artery disease; PCI has been shown ...
... Texas Health Presbyterian Hospital Dallas is the first major ... program that puts the care of ICU patients under ... oversee patient care in the ICU throughout the day ... is to have pulmonologists and other critical care physicians ...
... in Expanding Reach Across the Globe and Across ... 6 Z Trim Holdings, Inc. (OTC Bulletin ... agreed to an exclusive Israeli distributorship agreement with ... the supply of various high quality products for ...
... Feb. 6 Baxa Corporation, an Englewood Colorado-based medical device ... the Top 50 Family-Owned Companies in Colorado. Qualifying companies ... controlled by a single family, and controlling family members must ... to have been involved in the company for at least ...
... even when malignancy is found early , , FRIDAY, ... Ruth Bader Ginsburg will face tough challenges following her ... , At this point, it,s not clear exactly ... odds suggest pancreatic adenocarcinoma, which accounts for about 85 ...
... HIV+ Patients Receiving Dapsone Therapy at Significant Health Risk ... Feb. 6 Masimo (Nasdaq: MASI ), ... Low-Perfusion pulse oximetry, today announced that a new study ... Critical Care Congress suggests providers should consider routine screening ...
Cached Medicine News:Health News:Efficacy of stents is improved when their placement is determined by arterial blood flow measurement 2Health News:Texas Health Dallas' New Intensivist Program Puts Critical-Care Specialists in the ICU - All the Time 2Health News:Z Trim to be Distributed in Israel by Freya ICB 2Health News:Z Trim to be Distributed in Israel by Freya ICB 3Health News:Z Trim to be Distributed in Israel by Freya ICB 4Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Supreme Court Justice Ginsburg Faces Tough Battle Against Pancreatic Cancer 2Health News:Supreme Court Justice Ginsburg Faces Tough Battle Against Pancreatic Cancer 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 2Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 4
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... OAK, Mich. , March 26, 2015 ... have performed the Midwest,s first commercial implant of ... Administration for patients with non-valvular atrial fibrillation. The Watchman ... long-term use of blood-thinning warfarin medication to reduce the ... most common heart rhythm disorder affecting more than 5 ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... May 24, 2011 The National Community ... Competition and Consumer Choice Act of 2011 , ... the pharmacy of their choice, eliminate needless pharmaceutical ... abusive pharmacy audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ...
... May 24, 2011 A coalition of advocacy groups and ... for the District of Columbia Circuit to compel the Obama ... marijuana rescheduled under the provisions of the Controlled Substances Act ... would enable states with medical marijuana laws to expedite efforts ...
Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3Federal Court Asked to Compel Decision in Marijuana Scheduling Action 2Federal Court Asked to Compel Decision in Marijuana Scheduling Action 3
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Refkeratometer...
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
Medicine Products: